


10/805.806

=> s 60142-96-3/cn
L1 0 60142-96-3/CN

=> s 60142-96-3/rn
L2 1 60142-96-3/RN

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 60142-96-3 REGISTRY
ED Entered STN: 16 Nov 1984
CN Cyclohexaneacetic acid, 1-(aminomethyl)- (CA INDEX NAME)
OTHER NAMES:
CN 1-(Aminomethyl)cyclohexaneacetic acid
CN CI 945
CN Gabapen
CN Gabapentin
CN Go 3450
CN GOE 2450
CN GOE 3450
CN Neurontin
MF C9 H17 N O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM,
DDFU, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH,
IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*,
MSDS-OHS, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE,
TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1890 REFERENCES IN FILE CA (1907 TO DATE)
56 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1901 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> filecaplus
FILECAPLUS IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

10/923,271

=> file caplus		SINCE FILE	TOTAL
COST IN U.S. DOLLARS		ENTRY	SESSION
FULL ESTIMATED COST		8.07	8.28

FILE 'CAPLUS' ENTERED AT 18:20:49 ON 10 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Jul 2008 VOL 149 ISS 2
FILE LAST UPDATED: 9 Jul 2008 (20080709/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 60142-96-3 and tannic acid
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L4 1901 L3

8832 TANNIC
4623495 ACID
7178 TANNIC ACID
(TANNIC(W)ACID)
L5 5 L4 AND TANNIC ACID

=> s 15 and py<2003
22935557 PY<2003
L6 0 L5 AND PY<2003

```
=> d 15 1-5 bibi abs hitstr  
'BIBI' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'
```

The following are valid formats:

```
ABS ----- GI and AB  
ALL ----- BIB, AB, IND, RE  
APPS ----- AI, PRAI  
BIB ----- AN, plus Bibliographic Data and PI table (default)  
CAN ----- List of CA abstract numbers without answer numbers  
CBIB ----- AN, plus Compressed Bibliographic Data  
CLASS ----- IPC, NCL, ECLA, FTERM  
DALL ----- ALL, delimited (end of each field identified)  
DMAX ----- MAX, delimited for post-processing  
FAM ----- AN, PI and PRAI in table, plus Patent Family data  
FBIB ----- AN, BIB, plus Patent FAM  
IND ----- Indexing data  
IPC ----- International Patent Classifications  
MAX ----- ALL, plus Patent FAM, RE  
PATS ----- PI, SO  
SAM ----- CC, SX, TI, ST, IT  
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;  
SCAN must be entered on the same line as the DISPLAY,  
e.g., D SCAN or DISPLAY SCAN)  
STD ----- BIB, CLASS  
  
IABS ----- ABS, indented with text labels  
IALL ----- ALL, indented with text labels  
IBIB ----- BIB, indented with text labels  
IMAX ----- MAX, indented with text labels  
ISTD ----- STD, indented with text labels  
  
OBIB ----- AN, plus Bibliographic Data (original)  
OIBIB ----- OBIB, indented with text labels  
  
SBIB ----- BIB, no citations  
SIBIB ----- IBIB, no citations  
  
HIT ----- Fields containing hit terms  
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
containing hit terms  
HITRN ----- HIT RN and its text modification  
HITSTR ----- HIT RN, its text modification, its CA index name, and  
its structure diagram  
HITSEQ ----- HIT RN, its text modification, its CA index name, its  
structure diagram, plus NTE and SEQ fields  
FHITSTR ----- First HIT RN, its text modification, its CA index name, and  
its structure diagram  
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its  
structure diagram, plus NTE and SEQ fields  
KWIC ----- Hit term plus 20 words on either side  
OCC ----- Number of occurrence of hit term and field in which it occurs
```

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at

an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):end

=> d 15 1-5 ibib abs hitstr


L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:1005830 CAPLUS
 DOCUMENT NUMBER: 143:292591
 TITLE: In process conversion method for preparing tannate tablet, capsule or other solid dosage forms
 INVENTOR(S): Ware, Emily C.; Kiel, Jeffrey S.; Thomas, H. Greg; Ware, Brady Neal; Harned, George T.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 6 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050202080	A1	20050915	US 2005-78854	20050311
WO 2005089721	A1	20050929	WO 2005-US7826	20050311
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2004-552519P P 20040312

AB The present invention relates generally to the field of tannate chemical and more specifically to methods for processing tannate tablets, capsules, or other solid dosage forms. The present invention provides a novel manufacturing process for the conversion of one or more active pharmaceutical ingredients ("API") into their tannate salt complexes while incorporating the complexes into a therapeutic solid-dosage form which also may include non-tannate APIs. The first step of this process is to create a tannic acid powder blend by combining the salt or free base form of one or more APIs with tannic acid. After the dry blend is thoroughly mixed, a pharmaceutically acceptable liquid is added, for example by spraying, onto the dry powder blend facilitating the tannate salt conversion process. The conversion product is then added to addnl. dry powders thereby reducing the overall liquid content to a level

that is more typical of wet granulation processes.
 IT 60142-96-3DP, Gabapentin, tannate complexes
 RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)
 (in-process conversion method for preparing tannate tablets or other solid
 dosage forms)
 RN 60142-96-3 CAPLUS
 CN Cyclohexaneacetic acid, 1-(aminomethyl)- (CA INDEX NAME)




L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:803929 CAPLUS
 DOCUMENT NUMBER: 141:301482
 TITLE: Phenolic acid salts of gabapentin in liquid and/or
 semi-solid dosage forms and methods of use
 INVENTOR(S): Kiel, Jeffrey S.; Thomas, H. Greg; Mani, Narasimhan
 PATENT ASSIGNEE(S): Kiel Laboratories, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 6 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040192618	A1	20040930	US 2004-806260	20040322
US 7390922	B2	20080624		
WO 2004093867	A2	20041104	WO 2004-US7872	20040316
WO 2004093867	A3	20041202		
			W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
EP 1628656	A2	20060301	EP 2004-759602	20040316
R: DE, FR, GB, IT				
PRIORITY APPLN. INFO.:			US 2003-457408P	P 20030325
			WO 2004-US7872	W 20040316


AB The present invention relates to pharmaceutical compns. of gabapentin tannate, processes for production of those compns. and methods of use of those compns. The present invention provides a novel process for preparation of the

tannate salt of gabapentin in liquid or semi-solid dosage form for human and veterinary pharmaceutical use. Tannate salts of active pharmaceutical ingredients are used in sustained release applications and to improve certain organoleptic properties such as taste. The process may utilize either natural or synthetic tannic acid.

IT 60142-96-3, Gabapentin
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms)
 RN 60142-96-3 CAPLUS
 CN Cyclohexaneacetic acid, 1-(aminomethyl)- (CA INDEX NAME)



IT 60142-96-3DP, Gabapentin, tannate salts
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms)
 RN 60142-96-3 CAPLUS
 CN Cyclohexaneacetic acid, 1-(aminomethyl)- (CA INDEX NAME)



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:803928 CAPLUS
 DOCUMENT NUMBER: 141:301481
 TITLE: Process for preparing phenolic acid salts of gabapentin
 INVENTOR(S): Kiel, Jeffrey S.; Thomas, H. Greg; Mani, Narasimhan
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 5 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040192617	A1	20040930	US 2004-806022	20040322

WO 2004093866	A1 20041104	WO 2004-US7871	20040316
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

US 2003-457431P

P 20030325


AB The present invention provides a novel process for preparation of the tannate salt of gabapentin for human and veterinary pharmaceutical use. Tannate salts of active pharmaceutical ingredients are used in sustained release applications and to improve certain organoleptic properties such as taste. However, the prior art neither discloses nor suggests the preparation of gabapentin tannate. The process for preparing gabapentin tannate includes the mixing of gabapentin and tannic acid together in the presence of one or more solvents. The method may further include the step of selecting the one or more solvents from a group consisting of purified water, ethanol, glycerin, propylene glycol, diethylether, methylene chloride, acetone, iso-Pr alc. and mixts. thereof. The process may also include the steps of isolating and purifying the tannate salt. This may be accomplished by filtration, drying, centrifugation and lyophilization. The process may utilize either natural or synthetic tannic acid.

IT 60142-96-3, Gabapentin

RL: RCT (Reactant); RACT (Reactant or reagent)
(process for preparing phenolic acid salts of gabapentin)

RN 60142-96-3 CAPLUS


CN Cyclohexaneacetic acid, 1-(aminomethyl)- (CA INDEX NAME)



IT 60142-96-3DP, Gabapentin, tannate salts
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for preparing phenolic acid salts of gabapentin)

RN 60142-96-3 CAPLUS

CN Cyclohexaneacetic acid, 1-(aminomethyl)- (CA INDEX NAME)




L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:803927 CAPLUS
 DOCUMENT NUMBER: 141:301480
 TITLE: Phenolic acid salts of gabapentin in solid dosage forms and methods of use
 INVENTOR(S): Kiel, Jeffrey S.; Thomas, H. Greg; Mani, Narasimhan
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 5 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040192616	A1	20040930	US 2004-805806	20040322
WO 2004093827	A2	20041104	WO 2004-US8102	20040316
WO 2004093827	A3	20050310		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1622603	A2	20060208	EP 2004-759629	20040316
R: DE, FR, GB, IT				


PRIORITY APPLN. INFO.: US 2003-457399P P 20030325
WO 2004-US8102 W 20040316

- AB The present invention relates to pharmaceutical compns. of gabapentin tannate in solid dosage form, processes for production of those compns. and methods of use of those compns. Tannate salts of active pharmaceutical ingredients are used in sustained release applications and to improve certain organoleptic properties such as taste. The process may utilize either natural or synthetic tannic acid.
- IT 60142-96-3, Gabapentin
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (phenolic acid salts of gabapentin in solid dosage forms and methods of use)
- RN 60142-96-3 CAPLUS
 CN Cyclohexaneacetic acid, 1-(aminomethyl)- (CA INDEX NAME)



10/923,271

IT 60142-96-3DP, Gabapentin, tannate salts
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenolic acid salts of gabapentin in solid dosage forms and methods of use)
RN 60142-96-3 CAPLUS
CN Cyclohexaneacetic acid, 1-(aminomethyl)- (CA INDEX NAME)




L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:319273 CAPLUS
DOCUMENT NUMBER: 138:326578
TITLE: Process for preparing tannate tablet, capsule or other solid dosage forms
INVENTOR(S): Kiel, Jeffrey S.; Thomas, H. Greg; Mani, Narasimhan
PATENT ASSIGNEE(S): Kiel Laboratories, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 7 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030077321	A1	20030424	US 2002-269027	20021010
US 7273623	B2	20070925		
CA 2453256	A1	20031023	CA 2003-2453256	20030226
CA 2469736	A1	20031023	CA 2003-2469736	20030226
WO 2003086356 W: AU, CA, US	A1	20031023	WO 2003-US5664	20030226
WO 2003086346 W: AU, CA, US	A1	20031023	WO 2003-US5667	20030226
AU 2003217703	A1	20031027	AU 2003-217703	20030226
AU 2003217704	A1	20031027	AU 2003-217704	20030226
CA 2482013	A1	20040422	CA 2003-2482013	20030409
WO 2004032826	A2	20040422	WO 2003-US10918	20030409
WO 2004032826 W: CA RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	A3	20040826		
EP 1622586	A2	20060208	EP 2003-817708	20030409
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
US 20050069584	A1	20050331	US 2004-505347	20040819
US 20070020332	A1	20070125	US 2006-501649	20060809
PRIORITY APPLN. INFO.:			US 2001-328990P	P 20011012
			US 2001-282969P	P 20010410
			US 2002-119285	A 20020409

US 2002-269027	A 20021010
WO 2003-US5664	W 20030226
WO 2003-US5667	W 20030226
WO 2003-US10918	W 20030409
US 2004-921438	A2 20040819

- AB An active pharmaceutical ingredient is combined with tannic acid to form a tannate salt complex of the active ingredient. The active ingredient tannate salt complex without isolation or purification is then blended with pharmaceutically acceptable excipients to form a granulate which is processed into a tablet or capsule to generate a therapeutic solid dosage form. For example, tablets were prepared containing carbetapentane tannate 60.0 mg, chlorpheniramine tannate 4.0 mg, phenylephrine tannate 10.0 mg, magnesium aluminum silicate 30.0 mg, Avicel PH 102 459.642 mg, Methocel E-10 M 5.0 mg, corn starch 3.0 mg, calcium phosphate dibasic 10.133 mg, xanthan gum 7.875 mg, talc 2.25 mg, FD&C Red #40 0.85 mg, and magnesium stearate 2.25 mg.
- IT 60142-96-3D, Gabapentin, tannate
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of tannate tablet, capsule or other solid dosage forms)
- RN 60142-96-3 CAPLUS
- CN Cyclohexaneacetic acid, 1-(aminomethyl)- (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>